Provided by Tiger Fintech (Singapore) Pte. Ltd.

TuHURA Biosciences, Inc.

2.81
-0.0800-2.77%
Post-market: 2.80-0.0100-0.36%17:42 EDT
Volume:70.89K
Turnover:201.26K
Market Cap:122.74M
PE:-3.04
High:2.94
Open:2.91
Low:2.70
Close:2.89
Loading ...

TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody

Reuters
·
1 hour ago

BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private Offering

Reuters
·
03 Jun

Tuhura Biosciences-Plans to Use Net Proceeds From Offering to Fund Cash Requirements for Closing Proposed Merger With Kineta

THOMSON REUTERS
·
03 Jun

Tuhura Biosciences Inc -Secures $12.5 Mln of Commitments in a Private Offering

THOMSON REUTERS
·
03 Jun

Press Release: TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Dow Jones
·
03 Jun

TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025

Reuters
·
02 Jun

Tuhura Biosciences Presents Ifx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

THOMSON REUTERS
·
02 Jun

TuHURA Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
16 May

TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

TuHURA Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate

Benzinga
·
16 May

TuHURA Biosciences Reports Increased R&D and Administrative Expenses for Q1 2025; No Significant Revenue or Profit Data Provided

Reuters
·
16 May

BRIEF-TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update

Reuters
·
16 May

Tuhura Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
16 May

TuHURA Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
10 May

TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma

Reuters
·
05 May

Tuhura Biosciences Inc - FDA Agreement Reached to Lift Partial Clinical Hold on Phase 3 Trial of Ifx-2.0

THOMSON REUTERS
·
05 May

Tuhura Biosciences, Inc. Initiates Phase 1B/2a Study of Ifx-Hu2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (Mccup)

THOMSON REUTERS
·
05 May

Tuhura Biosciences Inc: Anticipates Initiating Phase 3 Registrational Trial of Ifx-2.0 in Q2

THOMSON REUTERS
·
05 May

Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Dow Jones
·
08 Apr

BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President

Reuters
·
07 Apr